MCM
IMCR icon

Moore Capital Management’s Immunocore IMCR Stock Holding History

Moore Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.72M Buy
274,663
+77,355
+39% +$2.29M 0.13% 143
2026
Q1 		$5.95M Buy
+197,308
New +$6.38M 0.12% 138

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Moore Capital Management's IMCR Position: Q2 2026 in Review

Moore Capital Management increased its Immunocore (IMCR) stake by 39% in Q2 2026, buying an estimated $2.29M and bringing the position to 274,663 shares worth $8.72M. The position accounts for 0.13% of the portfolio, ranked #143.

Moore Capital Management first reported a position in IMCR in Q1 2026 and has held it in 2 quarters since. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Moore Capital Management held 274,663 shares of Immunocore worth $8.72M as of Q2 2026.
  • Moore Capital Management bought 77,355 Immunocore shares in Q2 2026, an estimated $2.29M.
  • Immunocore made up 0.13% of Moore Capital Management's portfolio in Q2 2026, its #143 holding.
  • Moore Capital Management first reported a position in Immunocore in Q1 2026 and has held it in 2 quarters since.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.